Ruti Aga's Six-Year Ban: The Forged Prescription Cost Twice as Much as the Banned Substance

The most memorable detail in the Athletics Integrity Unit (AIU) file is not the name of the substance. It is an old prescription pad. The person who signed the prescription introduced herself as the treating physician. She was a family member of Ruti Aga. She held no medical registration number. When the AIU made enquiries, the clinic printed on the form said the prescription was not theirs. The woman then explained she had used an old pad from a previous workplace — which confirmed she had never worked there. Three independent checks. Three identical outcomes. Ruti Aga, 32, the 2026 Tokyo Marathon champion and a three-time runner-up at World Marathon Majors races, received a six-year ban effective from 10 September. The substance is only half the story. The other half is the piece of paper used to cover it up — and that half cost more than twice as much. To understand why six years landed like a shockwave in distance running, Aga needs to be placed correctly on the hierarchy. She did not emerge from a regional race. The 2026 Tokyo Marathon title put her in the top tier of global road racing. Three World Marathon Majors podium finishes across 2026–2026 confirm that was not a single-season spike. Among women marathoners, the number who hold that level for four consecutive years can be counted on one hand, and most of them carry Ethiopian or Kenyan passports. I have tracked East African women's road racing since 2026, and names like Aga appear with metronomic regularity in the upper half of major results sheets. The race that triggered the sanction took place in China in March: a half marathon, which she won. Her time was not disclosed in the file. That is the detail I regret most, because without a time there is no way to assess the course, the altitude, the conditions or the strength of the field. The location, however, says plenty: this was almost certainly an appearance-fee race, the kind that routinely invites East African athletes. The governance point matters: the adjudicating body was not the Chinese race organiser. It was the AIU — World Athletics' independent integrity arm, responsible for testing, results management and prosecution under the WADA Code. Before reaching the sanction, one classification error needs correcting, because most reporting makes it. Methylprednisolone is not an anabolic steroid. It is a synthetic glucocorticoid — a corticosteroid — sitting in WADA class S9, prohibited in-competition only, and designated a Specified Substance. Those three features change how the whole case reads. First, glucocorticoids have a common, legitimate use in treating knee-joint injuries, exactly as Aga claimed. Second, because the prohibition applies only in-competition, a treatment course outside a competition window can be entirely lawful. Third, Specified Substances are the class WADA acknowledges is more plausibly linked to inadvertent or therapeutic use, which makes the baseline sanction considerably softer than for an anabolic steroid. In 2026, when the pandemic shut the tracks, I opened Excel. An entire tournament sat in twenty thousand rows. That exercise taught me a rule: when an outcome looks absurd, break it into separate variables and add them back up. Applied here, the arithmetic is clean: two years for the presence of a prohibited substance, plus four years for tampering with evidence, served consecutively rather than concurrently, equals six. The WADA Code is explicit that multiple independent violations run consecutively — a detail most reports skip, leaving readers to assume six years was a single penalty inflated. The ratio is what deserves attention: the tampering portion is double the substance portion. In this system, the cover-up is punished more heavily than the underlying act. And here is why the AIU could go that far: the evidentiary chain left no room to argue. A named clinic confirmed the prescription was not theirs. The professional regulator confirmed the signatory held no registration. The former employer confirmed she had never been on staff. Every link was checked independently and every link broke. What I see is an amateur cover-up, not a sophisticated doping operation. Nobody built a shadow medical network; somebody borrowed an old pad from a relative. That amateurism is itself diagnostic of how thin the medical and legal support around the athlete was. Set beside a compliant path, the gap widens. With a genuine knee injury, the correct route is a Therapeutic Use Exemption (TUE) obtained in advance — or at minimum an honest declaration at testing, backed by verifiable medical records. In that scenario the substance side of the case, inherently the softer half because methylprednisolone is a Specified Substance, could plausibly have produced no violation at all, or a reduced sanction without aggravating factors. What turned an explicable treatment error into six years was the forged prescription. I hear stories like this in locker rooms. Now I retell them in numbers. There is a line I still use with young journalists: the Japanese do not run faster. They use the goalkeeper as a sixth piece. What I mean is this — when a result looks like it was decided by raw physicality, go looking for the mechanism behind it. In Aga's case, the mechanism behind six years is not the substance. It is the AIU's verification process, and the fact that process now moves fast enough that a fake prescription survives only days. The practical consequence for the whole system: forged medical paperwork is no longer a clever move. It is the move that converts a two-year ban into a six-year one. There is a paradox here that sports journalism rarely names. Aga's sanction is three times the baseline, and the reason is not the strength of the substance. The reason is that she had nobody beside her who understood the process well enough to handle the file properly. An elite marathoner earns most of her income from appearance fees and prize money. She has an agent, a coach, a training group. That structure rarely includes an integrity adviser — someone who knows a glucocorticoid course near competition needs a TUE, and knows that once you are caught, telling the truth costs a fraction of what forging costs. The counterintuitive point: the modern anti-doping system is built to forgive therapeutic error. It is not built to forgive manufactured evidence. And because most athletes in the East African road-racing pipeline have no dedicated legal counsel, the group that absorbs the heaviest sanctions is usually the group least equipped to defend itself. How the case is named in public also distorts perception. Calling methylprednisolone a steroid makes readers picture an athlete using muscle-building hormones. The reality is an anti-inflammatory used for joint treatment. The mislabel inflates perceived severity, and more importantly it erases the real lesson: the failure sits in medical documentation infrastructure, not in personal morality. At 32, Aga was inside the elite marathon peak window — a phase women can sustain past 35. A six-year ban pushes her return to roughly 38. Theoretically that is not impossible. Realistically, after six years away from competition, a return to World Marathon Majors podium level almost never happens. And with an Ethiopian pipeline deep enough that losing one contender barely shifts the competitive picture, her absence registers in the integrity column, not the results column. But the legacy of this case will not be Aga. It will be the very specific question East African federations now have to answer: who is teaching their athletes that a forged prescription can cost more than a correct course of treatment — and that the price is paid not in money but in an entire career.